Bhatia Neal
Division of Dermatology, Harbor UCLA Medical Center, Los Angeles, CA, USA.
J Drugs Dermatol. 2013 Jul 1;12(7):796-8.
Seborrheic dermatitis is one of those conditions that dermatologists and patients alike tend to find a routine for, and in many cases those routines are hard to break. And, unlike the new treatment paradigms for eczema, acne, and even actinic keratoses, combination therapies for addressing the disease process typically have not been a part of the approach to treating seborrheic dermatitis. However, with the advent of new therapies and vehicles as well as a better understanding of how neutrophils and free oxygen radicals impact inflammation,1 there are new options to maintain and control the disease process of seborrheic dermatitis to minimize flares. Although the needs of the scalp, face and chest are different, as are the variations in skin types, the fundamental mechanisms of the inflammatory process are often the same. If it is understood that seborrheic dermatitis is histologically classified as a papulosquamous disorder with paucineutrophilic and lymphocytic infiltrates, and if the trigger and etiologic agent most likely is Malassezia furfur, then the ideal mechanisms of action of therapies should be directed as such
脂溢性皮炎是皮肤科医生和患者都倾向于找到常规治疗方法的疾病之一,而且在很多情况下这些常规方法很难改变。并且,与湿疹、痤疮甚至光化性角化病的新治疗模式不同,针对脂溢性皮炎疾病进程的联合疗法通常并非治疗方法的一部分。然而,随着新疗法和药物载体的出现以及对中性粒细胞和游离氧自由基如何影响炎症有了更好的理解,现在有了新的选择来维持和控制脂溢性皮炎的疾病进程,以尽量减少病情发作。尽管头皮、面部和胸部的需求不同,皮肤类型也存在差异,但炎症过程的基本机制往往是相同的。如果认识到脂溢性皮炎在组织学上被归类为一种伴有少量中性粒细胞和淋巴细胞浸润的丘疹鳞屑性疾病,并且如果触发因素和病原体很可能是糠秕马拉色菌,那么理想的治疗作用机制就应如此定向。